Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis-Reference-Cited by-同舟云学术

Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis

Published:2022-12-10 Issue:5 Volume:200 Page:587-594
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Etekal Tommy¹^ORCID,Koehn Kelly²,Sborov Douglas W.³,McClune Brian³,Prasad Vinay⁴,Haslam Alyson⁵^ORCID,Berger Katherine⁶,Booth Christopher⁷,Al Hadidi Samer⁸^ORCID,Abdallah Al‐Ola²,Goodman Aaron⁹,Mohyuddin Ghulam Rehman³^ORCID

Affiliation:

1. Department of Radiation Sciences Umeå University Umeå Sweden

2. Division of Hematological Malignancies and Cellular Therapeutics University of Kansas Lawrence Kansas USA

3. Division of Hematology and Hematological Malignancies University of Utah Salt Lake City Utah USA

4. Division of Hematology/Oncology University of California San Francisco San Francisco California USA

5. Department of Epidemiology/Biostatistics University of California San Francisco San Francisco California USA

6. Patient Advocate University of Hartford West Hartford Connecticut USA

7. Division of Cancer Care and Epidemiology Queen's University Cancer Research Institute Kingston Ontario Canada

8. Myeloma Institute The University of Arkansas for Medical Sciences Little Rock Arkansas USA

9. Division of Blood and Marrow Transplantation University of California San Diego La Jolla California USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18568

Reference47 articles.

1. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials

2. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer

3. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival

4. FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma.2021;https://www.fda.gov/drugs/drug‐approvals‐and‐databases/fda‐grants‐accelerated‐approval‐melphalan‐flufenamide‐relapsed‐or‐refractory‐multiple‐myeloma. Accessed 3/14 2021.

5. FDA approves selinexor for refractory or relapsed multiple myeloma.2020;https://www.fda.gov/drugs/drug‐approvals‐and‐databases/fda‐approves‐selinexor‐refractory‐or‐relapsed‐multiple‐myeloma. Accessed 03/14 2021.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review;The Oncologist;2024-09-05

2. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma;Cancers;2024-08-23

3. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm;Blood Cancer Journal;2024-08-12

4. UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-Making;Cancer Management and Research;2024-07

5. Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial;The Lancet Haematology;2024-07